Tiziana Life Sciences Ltd.: Data from Secondary Progressive Multiple Sclerosis Patient Treated with Intranasal Treatment with Foralumab will be Presented at the Consortium of Multiple Sclerosis Centers (CMSC) 2022 Annual Meeting
NEW YORK, June 01, 2022) ("Tiziana" or the "Company"), a biotechnology company enabling breakthrough immunotherapies via novel routes of monoclonal antibody delivery, today announced that Dr. Tanuja Chitnis
United States Irina Koffler Hana Malik Tanuja Chitnis Lifesci Advisors Veterans Administration Ms Programs
Source: finanznachrichten.de